Recent assessment shows, in the first half of May 2025, Losartan Potassium prices in the Chinese market saw a slight increase, building on the upward momentum established in April. The market continued to experience a constrained supply environment, largely influenced by reduced inventory levels, front-loaded exports, and weakening domestic manufacturing output. These factors, combined with steady international demand, supported a firmer pricing trend in early May.

• Losartan Potassium prices in China went up a bit in early May 2025, following the trend in April due to supply shortage.
• Losartan Potassium supply was tight in April as Chinese exporters shipped out ahead of US tariffs and reduced domestic inventory.
• China’s industrial output and PMI went down in April, further reduced Losartan Potassium production capacity.
• International demand for Losartan Potassium was steady, with favorable exchange rate and lower freight cost, making exports more competitive.
• Losartan Potassium prices will go up in late May due to strong export and growing demand from key pharma sectors.

In April, Losartan Potassium prices in China went up as domestic suppliers rushed to export before the US tariffs came into effect. This front loading of shipments reduced the local inventory and tightened the supply in the market. Meanwhile, China’s official Purchasing Managers Index dropped to its lowest since December 2023, indicating overall industrial contraction and further reduced production capacity. The decrease in production put more pressure on the supply of active pharmaceutical ingredients like Losartan Potassium. And currency fluctuation also affected the pricing, as the depreciation of yuan against US dollar forced exporters to adjust the price to stay competitive.

In April, the demand for Losartan Potassium remained consistent due to continued purchasing from the pharmaceutical industry. Tariff unpredictability resulted in overseas buyers, notably from the United States, to purchase much earlier in the month, depleting inventories. Market signaling and less expensive freight from China to key global ports improved export economics. The stronger US dollar made Chinese pharmaceutical exports—including Losartan Potassium—more competitive in global markets. Together, these factors supported a healthy demand profile and supported stable to firm pricing considering supply constraints.

As of mid-May, pricing conditions have remained relatively firm, with tight supply and steady demand dynamics continuing to shape market behavior. According to market experts, Losartan Potassium prices in China are expected to increase further in the second half of May. High export volumes and growing demand from key downstream pharmaceutical sectors are anticipated to keep upward pressure on Losartan Potassium prices. Rising confidence within the domestic pharmaceutical manufacturing industry is also encouraging sustained procurement. As supply and demand reach a more balanced state, market fundamentals are likely to remain supportive of moderate price gains in the near term.